CYTOKININS
ADENINE
(Ade) [6-aminopurine]
MW 135.13; crystalline;
purity > 98% (HPLC) |
CAS:73-24-5; C5H5N5 |
|
001 0241 |
5 |
g |
001 0242 |
25 |
g |
001 0243 |
100 |
g |
001 0244 |
500 |
g |
ADENINE
HYDROCHLORIDE (Ade.HCl) [6-aminopurine hydrochloride]
MW 171.59; crystalline; purity > 98% (HPLC) |
CAS: 2922-28-3; C5H5N5.HCl |
water soluble |
|
|
001
3261 |
5 |
g |
001
3262 |
25 |
g |
001
3263 |
100 |
g |
ADENINE
HEMISULFATE (Ade.1/2H2SO4)
[6-aminopurine hemisulfate]
MW 184.17; crystalline; purity > 98% (HPLC) |
CAS: 321-30-2; C5H5N5.1/2H2SO4 |
|
001
3271 |
5 |
g |
001
3272 |
25 |
g |
001
3273 |
100 |
g |
ADENOSINE (Ado)
[6-amino-9-β-D-ribofuranosylpurine]
MW
267.25; crystalline;
purity > 98% (HPLC) |
CAS:
58-61-7; C10H13N5O4 |
|
001 6301 |
5 |
g |
001 6302 |
25 |
g |
001 6303 |
100 |
g |
001 6304 |
500 |
g |
N6-BENZYLADENINE (BA) [6 - benzylaminopurine]
MW 225.25; crystalline; purity > 98% (HPLC) |
CAS: 1214-39-7; C12H11N5 |
|
001
0221 |
1 |
g |
001
0222 |
5 |
g |
001 0223 |
25 |
g |
001 0224 |
100 |
g |
N6-BENZYLADENINE HYDROCHLORIDE (BA.HCl) [6 - benzylaminopurine hydrochloride]
MW 261.71; crystalline; purity > 98% (HPLC) |
CAS: 162714-86-5; C12H11N5.HCl |
water soluble |
|
|
001
0181 |
250 |
mg |
001
0182 |
1 |
g |
001
0183 |
5 |
g |
N6-BENZYLADENOSINE (BAR) [6-benzylamino-9-β-D-ribofuranosylpurine]
MW 357.37;
crystalline; purity > 98% (HPLC) |
CAS: 4294-16-0; C17H19N5O4 |
|
001
0551 |
100 |
mg |
001
0552 |
250 |
mg |
001
0553 |
1 |
g |
001 0554 |
5 |
g |
N6-BENZYLADENINE-3-GLUCOSIDE
(BA3G) [6-benzylamino-3-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) |
CAS: 56159-41-2; C18H21N5O5 |
|
001
0581 |
1 |
mg |
001
0582 |
2 |
mg |
001
0583 |
5 |
mg |
N6-BENZYLADENINE-7-GLUCOSIDE
(BA7G) [6-benzylamino-7-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) |
CAS: 56159-42-3; C18H21N5O5 |
|
001
0571 |
1 |
mg |
001
0572 |
2 |
mg |
001
0573 |
5 |
mg |
N6-BENZYLADENINE-9-GLUCOSIDE
(BA9G) [6-benzylamino-9-β-D-glucopyranosylpurine]
MW 387.40; crystalline; purity > 95% (HPLC ) |
CAS: 4294-17-1; C18H21N5O5 |
|
001 3281 |
1 |
mg |
001 3282 |
2 |
mg |
001 3283 |
5 |
mg |
N6-BENZYL-9-(2-TETRAHYDROPYRANYL)ADENINE
(BPA)
MW 309.37; crystalline; purity > 98% (HPLC ) |
CAS: 2312-73-4; C17H19N5O |
|
001
3291 |
100 |
mg |
001
3292 |
500 |
mg |
001
3293 |
1 |
g |
001 3294 |
5 |
g |
N6 - BENZYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (BAMP) [6-benzylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium
monohydrate]
MW 499.34; crystalline;
purity > 95% (HPLC) |
CAS: 13484-66-7; C17H18N5Na2O7P.H2O |
|
001
5001 |
1 |
mg |
001
5002 |
2 |
mg |
001
5003 |
5 |
mg |
N-(2-CHLORO-4-PYRIDYL)-N'-PHENYLUREA (CPPU,4-CPPU)
MW 247.69; crystalline; purity > 98% (HPLC) |
CAS: 68157-60-8; C10H12ClN3O |
|
001
0191 |
100 |
mg |
001
0192 |
250 |
mg |
001
0193 |
1 |
g |
N6 - CYCLOPENTYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (MP) [6-cyclopentylamino-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW
459.31; CRYSTALLINE;
purity > 97% (HPLC) |
CAS: 117778-38-8; C15H20N5Na2O7P.H2O |
|
001
6261 |
1 |
mg |
001
6262 |
2 |
mg |
001
6263 |
5 |
mg |
DIHYDROZEATIN (DZ)
[6-(4-hydroxy-3-methylbutylamino)purine]
MW 221.26; crystalline; purity > 99% (HPLC) |
CAS: 14894-18-9; C10H15N5O |
|
001
0601 |
5 |
mg |
001
0602 |
10 |
mg |
001
0603 |
50 |
mg |
001
0604 |
250 |
mg |
001
0605 |
1 |
g |
DIHYDROZEATIN HYDROCHLORIDE (DZ.HCl)
[6-(4-hydroxy-3-methylbutylamino)purine
hydrochloride]
MW 257.72; crystalline; purity > 98% (HPLC) |
CAS: 1402800-82-1; C10H15N5O.HCl |
water
soluble |
|
|
001
0251 |
10 |
mg |
001
0252 |
50 |
mg |
001
0253 |
250 |
mg |
DIHYDROZEATIN RIBOSIDE (DZR) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosylpurine]
MW 353.38; crystalline; purity > 98% (HPLC) |
CAS: 22663-55-4; C15H23N5O5 |
|
001
0611 |
5 |
mg |
001
0612 |
10 |
mg |
001 0613 |
50 |
mg |
001 0614 |
250 |
mg |
001 0615 |
1 |
g |
DIHYDROZEATIN-7-GLUCOSIDE (DZ7G) [6-(4-hydroxy-3-methylbutylamino)-7-β-D-glucopyranosylpurine]
MW 383.41;
crystalline; purity > 95% (HPLC) |
CAS: 91599-03-0; C16H25N5O6 |
|
001
0621 |
1 |
mg |
001
0622 |
2 |
mg |
001
0623 |
5 |
mg |
DIHYDROZEATIN-9-GLUCOSIDE (DZ9G) [6-(4-hydroxy-3-methylbutylamino)-9-β-D-glucopyranosylpurine]
MW 383.41;
crystalline; purity > 95% (HPLC) |
CAS: 73263-99-7; C16H25N5O6 |
|
001
0631 |
1 |
mg |
001
0632 |
2 |
mg |
001
0633 |
5 |
mg |
DIHYDROZEATIN-O-GLUCOSIDE (DZOG) [6-(4-β-D-glucopyranosyloxy-3-methylbytylamino)purine]
MW 383.41;
crystalline; purity > 95% (HPLC) |
CAS: 62512-96-3; C16H25N5O6 |
|
001
0641 |
1 |
mg |
001
0642 |
2 |
mg |
001
0643 |
5 |
mg |
DIHYDROZEATIN-O-GLUCOSIDE RIBOSIDE (DZROG)
[6-(4-β-D-glucopyranosyloxy-3-methylbutyl)amino-9-β-D-purine ribofuranosyl]
MW 515.52;
crystalline; purity > 95% (HPLC) |
CAS: 62512-95-2; C21H33N5O10 |
|
001
0651 |
1 |
mg |
001
0652 |
2 |
mg |
001
0653 |
5 |
mg |
DIHYDROZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (DZRMP)
[6-(4-hydroxy-3-methylbutylamino)-9-β-D-ribofuranosyl
purine-5'-monophosphate disodium monohydrate]
MW 495.34; crystalline; purity > 95% (HPLC) |
CAS: 31284-94-3; C15H22N5Na2O8P.H2O |
|
001
5011 |
1 |
mg |
001
5012 |
2 |
mg |
001
5013 |
5 |
mg |
DIHYDROZEATIN-O-ACETYL (AcDZ)
[6-(4-acetoxy-3-methylbutylamino)purine]
MW 263.30;
crystalline; purity > 98% (HPLC) |
CAS: 126221-88-3; C12H17N5O2 |
|
001
5021 |
5 |
mg |
001
5022 |
10 |
mg |
001
5023 |
50 |
mg |
N6-(3-FLUOROBENZYL)ADENINE (mFBA) [6 - (3-fluorobenzylamino)purine]
MW 243.25; crystalline; purity > 98% (HPLC) |
CAS: 525608-36-0; C12H10FN5 |
|
001
5801 |
100 |
mg |
001
5802 |
500 |
mg |
001 5803 |
1 |
g |
N6-(3-FLUOROBENZYL)ADENOSINE (mFBAR)[6-(3-fluorobenzylamino)-9-β-D-ribofuranosylpurine]
MW 375.36; crystalline; purity > 98% (HPLC) |
CAS: 29204-64-6; C17H18FN5O4 |
|
001
5811 |
100 |
mg |
001
5812 |
500 |
mg |
001 5813 |
1 |
g |
001 5814 |
5 |
g |
FUSATINE () [6-(3-Methylpyrrol-1-yl)-9H-purine]
MW 199.22; crystalline; purity > 97% (HPLC) |
CAS: 33917-73-6; C10H9N5 |
|
001
7821 |
1 |
mg |
001
7822 |
2 |
mg |
001 7823 |
5 |
mg |
2-CHLORO-FUSATINE () [2-Chloro-6-(3-Methylpyrrol-1-yl)-9H-purine]
MW 233.66; crystalline; purity > 97% (HPLC) |
CAS: N/A; C10H9ClN5 |
|
001
7831 |
1 |
mg |
001
7832 |
2 |
mg |
001 7833 |
5 |
mg |
HYPOXANTHINE (Hyp) [6-hydroxypurine]
MW 136.11; crystalline; purity > 98% ( HPLC ) |
CAS: 68-94-0; C5H4N4O |
|
001
5941 |
5 |
g |
001
5942 |
25 |
g |
001
5943 |
100 |
g |
N6-ISOPENTENYLADENINE (iP) [6-(3,3-dimethylallylamino)purine]
MW 203.25; crystalline; purity > 99% (HPLC) |
CAS: 2365-40-4; C10H13N5 |
|
001
0161 |
1 |
g |
001
0162 |
5 |
g |
001 0163 |
10 |
g |
001 0164 |
25 |
g |
N6-ISOPENTENYLADENINE HYDROCHLORIDE (iP.HCl) [6-(3,3-dimethylallylamino)purine hydrochloride]
MW 239.71;
crystalline; purity > 98% (HPLC) |
CAS: 177966-67-5; C10H13N5.HCl |
water soluble |
|
|
001
5031 |
1 |
g |
001
5032 |
5 |
g |
001
5033 |
10 |
g |
N6-ISOPENTENYLADENOSINE (iPR) [6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
MW 335.37;
crystalline; purity > 99% (HPLC) |
CAS: 7724-76-7; C15H21N5O4 |
|
001
0171 |
100 |
mg |
001
0172 |
250 |
mg |
001
0173 |
1 |
g |
2-BENZYLTHIO-N6-ISOPENTENYLADENINE (2BSiP)[2-benzylthio-6-(3,3-dimethylallylamino)purine]
MW 325.44;
crystalline; purity > 98% (HPLC) |
CAS: 52172-11-9; C17H19N5S |
|
001
5241 |
5 |
mg |
001
5242 |
10 |
mg |
001
5243 |
50 |
mg |
2-METHYLTHIO-N6-ISOPENTENYLADENINE (2MeSiP) [2-methylthio-6-(3,3-dimethylallylamino)purine]
MW 249.34;
crystalline; purity > 98% (HPLC) |
CAS: 20758-33-2; C11H15N5S |
|
001
5071 |
1 |
mg |
001
5072 |
2 |
mg |
001
5073 |
5 |
mg |
2-METHYLTHIO-N6-ISOPENTENYLADENOSINE (2MeSiPR)
[2-methylthio-6-(3,3-dimethylallylamino)-9-β-D-ribofuranosylpurine]
MW 381.46;
CRYSTALLINE; purity > 95%
(HPLC) |
CAS: 20859-00-1; C16H23N5O4S |
|
001
5061 |
1 |
mg |
001
5062 |
2 |
mg |
001
5063 |
5 |
mg |
2-MERCAPTO-N6-ISOPENTENYLADENINE (2SiP) [2-mercapto-6-(3,3-dimethylallylamino)purine]
MW 235.31;
crystalline; purity > 95% (HPLC) |
CAS: 52172-12-0; C10H13N5S |
|
001
5081 |
1 |
mg |
001
5082 |
2 |
mg |
001
5083 |
5 |
mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE (iP3GN)
MW
379.38; CRYSTALLINE; purity > 97% (HPLC) |
CAS: 147663-48-7; C16H21N5O6 |
|
001 5981 |
5 |
mg |
001 5982 |
25 |
mg |
001 5983 |
50 |
mg |
N6-ISOPENTENYLADENINE-3-GLUCURONIDE amide (iP3GNA)
MW 378.39; CRYSTALLINE; purity > 98% (HPLC) |
CAS: 1402800-75-2; C16H22N6O5
|
|
001 5991 |
5 |
mg |
001 5992 |
25 |
mg |
001 5993 |
50 |
mg |
N6-ISOPENTENYLADENOSINE-5'-MONOPHOSPHATE SODIUM SALT (iPMP) [6-(3,3-dimethylallylamino)-9-b-D-ribofuranosylpurine-5'-monophosphate
disodium monohydrate]
MW 477.33; crystalline; purity > 95% (HPLC) |
CAS: 20268-93-3; C15H20N5Na2O7P.H2O |
|
001
5041 |
1 |
mg |
001
5042 |
2 |
mg |
001
5043 |
5 |
mg |
N6-ISOPENTENYLADENINE-7-GLUCOSIDE (iP7G) [6-(3,3-dimethylallylamino)-7-β-D-glucopyranosylpurine]
MW 365.39; crystalline; purity > 95% (HPLC) |
CAS: 59384-58-6; C16H23N5O5 |
|
001
5051 |
1 |
mg |
001
5052 |
2 |
mg |
001
5053 |
5 |
mg |
N6-ISOPENTENYLADENINE-9-GLUCOSIDE (iP9G) [6-(3,3-dimethylallylamino)-9-β-D-glucopyranosylpurine]
MW 365.39; crystalline; purity > 95% (HPLC) |
CAS: 83087-94-9; C16H23N5O5 |
|
001 0231 |
1 |
mg |
001 0232 |
2 |
mg |
001 0233 |
5 |
mg |
KINETIN (K) [6-furfurylaminopurine]
MW 215.22;
crystalline; purity > 99% (HPLC) |
CAS: 525-79-1; C10H9N5O |
|
001
0341 |
250 |
mg |
001
0342 |
1 |
g |
001
0343 |
5 |
g |
001
0344 |
25 |
g |
KINETIN HYDROCHLORIDE(K.HCl) [6-furfurylaminopurine hydrochloride]
MW 251.68;
crystalline; purity > 98% (HPLC) |
CAS: 177966-68-6; C10H9N5O.HCl |
water soluble |
|
|
001 0261 |
100 |
mg |
001 0262 |
500 |
mg |
001 0263 |
1 |
g |
KINETIN RIBOSIDE (KR) [6 - furfurylamino-9-b-D-ribofuranosylpurine]
MW 347.33;
crystalline; purity > 99% (HPLC) |
CAS: 4338-47-0; C15H17N5O5 |
|
001
0351 |
100 |
mg |
001
0352 |
250 |
mg |
001
0353 |
1 |
g |
001
0354 |
5 |
g |
KINETIN-3-GLUCOSIDE (αK3G) [6-furfurylamino-3-α-D-glucopyranosylpurine]
MW 377.36;
crystalline; purity > 95% (HPLC ) |
CAS: 900786-14-3; C16H19N5O6 |
|
001
5771 |
1 |
mg |
001 5772 |
2 |
mg |
001 5773 |
5 |
mg |
KINETIN-9-GLUCOSIDE (K9G) [6-furfurylamino-9-β-D-glucopyranosylpurine]
MW 377.36;
crystalline; purity > 95% (HPLC ) |
CAS: 98177-43-6; C16H19N5O6 |
|
001 0441 |
1 |
mg |
001 0442 |
2 |
mg |
001 0443 |
5 |
mg |
KINETIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (KMP) [6-furfurylamino-9-β-D-ribofuranosylpurine-5'-monophosphate
disodium monohydrate]
MW 489.30; crystalline; purity > 95% (HPLC) |
CAS: 13484-67-8; C15H16N5Na2O8P.H2O |
|
001
5091 |
1 |
mg |
001
5092 |
2 |
mg |
001
5093 |
5 |
mg |
NEBULARINE (NEB) [9-(β-D-ribofuranosylpurine]
MW 286.68; crystalline; purity > 97% (HPLC) |
CAS: 550-33-4; C10H12N4O4 |
|
001
9721 |
1 |
mg |
001
7922 |
2 |
mg |
001
7923 |
5 |
mg |
PHENYLADENINE
[6-phenylaminopurine, 6-anilinopurine]
MW 211.23; crystalline;
purity > 95% (HPLC) |
CAS:1210-66-8; C11H9N5 |
|
001 6971 |
100 |
mg |
001 6972 |
500 |
mg |
001 6973 |
1 |
g |
THIDIAZURON (TDZ) [N-phenyl-N'-(1,2,3-thiadiazol-5-yl)urea]
MW 220.25;
crystalline; purity > 98% (HPLC ) |
CAS: 51707-55-2; C9H8N4OS |
|
001
3161 |
5 |
mg |
001
3162 |
25 |
mg |
001
3163 |
250 |
mg |
001
3164 |
1 |
g |
001
3165 |
5 |
g |
meta-TOPOLIN
(mT) [6-(3-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity >98% (HPLC) |
CAS: 75737-38-1; C12H11N5O |
|
001
0101 |
100 |
mg |
001
0102 |
500 |
mg |
001
0103 |
1 |
g |
001
0104 |
5 |
g |
001
0105 |
25 |
g |
meta-TOPOLIN
RIBOSIDE (mTR) [6-(3-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline;purity >99% (HPLC) |
CAS: 110505-76-5; C17H19N5O5 |
|
001
0111 |
100 |
mg |
001
0112 |
500 |
mg |
001
0113 |
1 |
g |
meta-TOPOLIN DEOXYRIBOSIDE (mTdR) [6-(3-hydroxybenzylamino)-2 -deoxy-9-b-D-ribofuranosylpurine]
MW 357.37; crystalline;purity >99% (HPLC) |
CAS: 1947401-10-6; C17H19N5O4 |
|
001 8031 |
1 |
mg |
001 8032 |
5 |
mg |
001 8033 |
25 |
mg |
meta-TOPOLIN-9-GLUCOSIDE (mT9G) [6-(3-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: 179528-30-4; C18H21N5O6 |
|
001 0141 |
1 |
mg |
001 0142 |
2 |
mg |
001 0143 |
5 |
mg |
meta-TOPOLIN-7-GLUCOSIDE (mT7G) [6-(3-hydroxybenzylamino)-7-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: N/A; C18H21N5O6 |
|
001 7861 |
100 | µg |
001 7862 |
200 | µg |
001 7863 |
500 | µg |
meta-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (mTMP) [6-(3-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium
monohydrate]
MW 515.34; crystalline;
purity > 95% (HPLC) |
CAS: 946853-27-6; C17H18N5Na2O8P.H2O |
|
001
6841 |
1 |
mg |
001
6842 |
2 |
mg |
001
6843 |
5 |
mg |
meta-TOPOLIN-9-TETRAHYDROPYRANYL (mTTHP) [6-(3-hydroxybenzylamino)purine-9-(2-tetrahydropyranyl]
MW 325.37; crystalline;
purity > 97% (HPLC) |
CAS: 1144854-40-9; C17H19N5O2 |
|
001
7551 |
100 |
mg |
001
7552 |
500 |
mg |
001
7553 |
1 |
g |
ortho-TOPOLIN (oT) [6-(2-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity > 99% (HPLC) |
CAS: 20366-83-0; C12H11N5O |
|
001
0121 |
100 |
mg |
001
0122 |
500 |
mg |
001
0123 |
1 |
g |
ortho-TOPOLIN RIBOSIDE (oTR)[6-(2-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline; purity > 99% (HPLC) |
CAS: 50868-58-1; C17H19N5O5 |
|
001
0131 |
100 |
mg |
001
0132 |
500 |
mg |
001
0133 |
1 |
g |
ortho-TOPOLIN-9-GLUCOSIDE (oT9G) [6-(2-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: 160299-96-7; C18H21N5O6 |
|
001 0151 |
1 |
mg |
001 0152 |
2 |
mg |
001 0153 |
5 |
mg |
ortho-TOPOLIN-7-GLUCOSIDE (oT7G) [6-(2-hydroxybenzylamino)-7-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: N/A; C18H21N5O6 |
|
001 7871 |
100 | µg |
001 7872 |
200 | µg |
001 7873 |
500 | µg |
ortho-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (oTMP) [6-(2-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium
monohydrate]
MW 515.34; crystalline;
purity > 95% (HPLC) |
CAS: 1242061-01-3; C17H18N5Na2O8P.H2O |
|
001
6831 |
1 |
mg |
001
6832 |
2 |
mg |
001
6833 |
5 |
mg |
para-TOPOLIN (pT) [6-(4-hydroxybenzylamino)purine]
MW 241.25; crystalline; purity > 99% (HPLC) |
CAS: 80054-30-4; C12H11N5O |
|
001
0451 |
100 |
mg |
001
0452 |
500 |
mg |
001
0453 |
1 |
g |
para-TOPOLIN RIBOSIDE (pTR) [6-(4-hydroxybenzylamino)-9-b-D-ribofuranosylpurine]
MW 373.37; crystalline; purity > 99% (HPLC) |
CAS: 23666-24-2; C17H19N5O5 |
|
001
0461 |
100 |
mg |
001
0462 |
500 |
mg |
001
0463 |
1 |
g |
para-TOPOLIN-9-GLUCOSIDE (pT9G) [6-(4-hydroxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: 1046433-04-8; C18H21N5O6 |
|
001
0401 |
1 |
mg |
001
0402 |
2 |
mg |
001
0403 |
5 |
mg |
para-TOPOLIN-7-GLUCOSIDE (pT7G) [6-(4-hydroxybenzylamino)-7-β-D-glucopyranosylpurine]
MW 403.40;
crystalline; purity >95% (HPLC) |
CAS: N/A; C18H21N5O6 |
|
001 7881 |
100 | µg |
001 7882 |
200 | µg |
001 7883 |
500 | µg |
para-TOPOLIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (pTMP) [6-(4-hydroxybenzylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium
monohydrate]
MW 515.34; crystalline;
purity > 95% (HPLC) |
CAS: 1402800-77-4; C17H18N5Na2O8P.H2O |
|
001
6851 |
1 |
mg |
001
6852 |
2 |
mg |
001
6853 |
5 |
mg |
ortho-METHOXYTOPOLIN (MeoT) [6-(2-methoxybenzylamino)purine]
MW 255.28;
crystalline; purity > 99% (HPLC) |
CAS: 75737-41-6; C13H13N5O |
|
001
0491 |
100 |
mg |
001
0492 |
500 |
mg |
001
0493 |
1 |
g |
ortho-METHOXYTOPOLIN
RIBOSIDE (MeoTR) [6-(2-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
MW 387.40; crystalline; purity > 99% (HPLC) |
CAS: 23660-98-2; C18H21N5O5 |
|
001
0501 |
100 |
mg |
001
0502 |
500 |
mg |
001
0503 |
1 |
g |
ortho-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(2-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43;
crystalline;
purity > 95% (HPLC) |
CAS: 1226978-27-7; C19H23N5O6 |
|
001 5861 |
1 |
mg |
001 5862 |
2 |
mg |
001 5863 |
5 |
mg |
meta-METHOXYTOPOLIN (MemT) [6-(3-methoxybenzylamino)purine]
MW 255.28;
crystalline; purity > 99% (HPLC) |
CAS: 75737-39-2; C13H13N5O |
|
001
0511 |
100 |
mg |
001
0512 |
500 |
mg |
001
0513 |
1 |
g |
meta-METHOXYTOPOLIN RIBOSIDE (MemTR) [6-(3-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
MW 387.40; crystalline; purity > 99% (HPLC) |
CAS: 101565-95-1; C18H21N5O5 |
|
001
0531 |
100 |
mg |
001
0532 |
500 |
mg |
001
0533 |
1 |
g |
meta-METHOXYTOPOLIN-9-GLUCOSIDE (MeoT9G) [6-(3-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43;
crystalline;
purity > 95% (HPLC) |
CAS: 1226978-22-8; C19H23N5O6 |
|
001 5871 |
1 |
mg |
001 5872 |
2 |
mg |
001 5873 |
5 |
mg |
meta-METHOXYTOPOLIN-9-TETRAHYDROPYRANYL (MemTTHP) [6-(3-methoxybenzylamino)purine-9-(2-tetrahydropyranyl)
MW 339.40;
crystalline;
purity > 97% (HPLC) |
CAS: 1000853-88-2; C18H21N5O2 |
|
001 7561 |
100 |
mg |
001 7562 |
500 |
mg |
001 7563 |
1 |
g |
2-CHLORO-6-(3-METHOXYBENZYLAMINO)PURINE (2Cl-MemT, RR-D)
MW 289.73;
crystalline; purity > 98% (HPLC) |
CAS: 185408-93-9; C13H12ClN5O |
|
001
7661 |
100 |
mg |
001
7662 |
500 |
mg |
001
7663 |
1 |
g |
para-METHOXYTOPOLIN
RIBOSIDE (MepTR) [6-(4-methoxybenzylamino)-9-β-D-ribofuranosylpurine]
MW 387.40; crystalline; purity > 99% (HPLC) |
CAS: 23666-24-2; C18H21N5O5 |
|
001
0521 |
100 |
mg |
001
0522 |
500 |
mg |
001
0523 |
1 |
g |
para-METHOXYTOPOLIN-9-GLUCOSIDE (MepT9G) [6-(4-methoxybenzylamino)-9-β-D-glucopyranosylpurine]
MW 417.43;
crystalline;
purity > 95% (HPLC) |
CAS: NONE; C19H23N5O6 |
|
001 5881 |
1 |
mg |
001 5882 |
2 |
mg |
001 5883 |
5 |
mg |
trans-ZEATIN (tZ) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25;
crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% |
CAS: 1637-39-4; C10H13N5O |
|
001
0301 |
5 |
mg |
001
0302 |
10 |
mg |
001 0303 |
100 |
mg |
001 0304 |
1 |
g |
trans-ZEATIN HYDROCHLORIDE (tZ.HCl)
[6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine hydrochloride]
MW 255.71; crystalline; purity > 97% (HPLC) |
CAS: 6025-81-6; C10H13N5O.HCl |
water soluble |
|
|
001
5101 |
100 |
mg |
001
5102 |
250 |
mg |
001 5103 |
1 |
g |
trans-ZEATIN RIBOSIDE (tZR) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 99% (HPLC); white crystalls; cis-isomer < 0.05% |
CAS: 6025-53-2; C15H21N5O5 |
|
001
0311 |
5 |
mg |
001
0312 |
10 |
mg |
001 0313 |
100 |
mg |
001 0314 |
1 |
g |
ZEATIN mixed isomers (E/Z) equal mixture of cis- and trans- isomers
[6-(4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25;
crystalline; purity > 98% (HPLC) |
CAS: 13114-27-7; C10H13N5O |
|
001
3171 |
5 |
mg |
001
3172 |
10 |
mg |
001
3173 |
100 |
mg |
001
3174 |
1 |
g |
ZEATIN RIBOSIDE mixed isomers (E/Z)
equal mixture of cis- and trans- isomers
[6-(4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 98% (HPLC) |
CAS: 28542-78-1; C15H21N5O5 |
|
001
3181 |
5 |
mg |
001
3182 |
10 |
mg |
001
3183 |
100 |
mg |
001
3184 |
1 |
g |
trans-ZEATIN-7-GLUCOSIDE (tZ7G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-7-b-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) |
CAS: 38165-56-9; C16H23N5O6 |
|
001
5111 |
1 |
mg |
001
5112 |
2 |
mg |
001
5113 |
5 |
mg |
trans-ZEATIN-9-GLUCOSIDE (tZ9G) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) |
CAS: 51255-96-0; C16H23N5O6 |
|
001 0471 |
1 |
mg |
001 0472 |
2 |
mg |
001 0473 |
5 |
mg |
trans-ZEATIN-9-GLUCURONIDE (tZ9GN)
MW 395.38; crystalline; purity > 95% (HPLC) |
CAS: 1402800-77-4; C16H21N5O7 |
|
001
5961 |
5 |
mg |
001
5962 |
10 |
mg |
001
5963 |
50 |
mg |
trans-ZEATIN-O-GLUCOSIDE (tZOG)
[6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
MW 381.39; crystalline; purity > 95% (HPLC) |
CAS: 56329-06-7; C16H23N5O6 |
|
001
5121 |
1 |
mg |
001
5122 |
2 |
mg |
001
5123 |
5 |
mg |
trans-ZEATIN-O-GLUCURONIDE (tZOGN)
MW
395.38; CRYSTALLINE; purity > 95% (HPLC) |
CAS: 147663-51-2; C16H21N5O7 |
|
001 5971 |
5 |
mg |
001 5972 |
10 |
mg |
001 5973 |
50 |
mg |
trans-ZEATIN-O-GLUCOSIDE RIBOSIDE (tZROG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW 513.51; crystalline; purity > 95% (HPLC) |
CAS: 62512-97-4; C21H31N5O10 |
|
001
5131 |
1 |
mg |
001
5132 |
2 |
mg |
001
5133 |
5 |
mg |
trans-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (tZMP) [6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate
disodium monohydrate]
MW 493.33; crystalline; purity > 95% (HPLC) |
CAS: 25615-16-1; C15H20N5Na2O8P.H2O |
|
001
5141 |
1 |
mg |
001
5142 |
2 |
mg |
001
5143 |
5 |
mg |
trans-ZEATIN-9-GLUCOSIDE-O-GLUCOSIDE (tZ9GOG) [6-((E)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW
543.64;
crystalline; purity > 95% (HPLC) |
CAS: 115921-05-6; C22H33N5O11 |
|
001
5501 |
1 |
mg |
001
5502 |
2 |
mg |
001
5503 |
5 |
mg |
trans-ZEATIN-O-ACETYL (ActZ)
[6-((E)-4-acetoxy-3-methylbut-2-enylamino)purine]
MW 261.29;
crystalline; purity > 98% (HPLC) |
CAS: 6025-82-7; C12H15N5O2 |
|
001
5151 |
1 |
mg |
001
5152 |
2 |
mg |
001
5153 |
5 |
mg |
2-CHLORO-trans-ZEATIN (2CltZ) [2-chloro-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 253.69;
crystalline; purity > 98% (HPLC) |
CAS: 29736-30-9; C10H12ClN5O |
|
001
5161 |
5 |
mg |
001
5162 |
10 |
mg |
001
5163 |
50 |
mg |
RS (+/-)-trans-METHYLZEATIN (t-1 -MZ) [6-((E)-4-hydroxy-3-methylpent-2-enylamino)purine]
MW 233.28;
crystalline; purity > 98% (HPLC) |
CAS: 143168-20-1; C11H15N5 |
|
001
7911 |
1 |
mg |
001
7912 |
2 |
mg |
001
7913 |
5 |
mg |
2-METHYLTHIO-trans-ZEATIN (2MeStZ) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 265.34;
crystalline; purity > 95% (HPLC) |
CAS: 29736-33-2; C11H15N5OS |
|
001
5171 |
1 |
mg |
001
5172 |
2 |
mg |
001
5173 |
5 |
mg |
2-METHYLTHIO-trans-ZEATIN RIBOSIDE (2MeStZR) [2-methylthio-6-((E)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
MW 397.46; crystalline; purity > 95% (HPLC) |
CAS: 53274-45-6; C16H23N5O5S |
|
001
5181 |
1 |
mg |
001
5182 |
2 |
mg |
001
5183 |
5 |
mg |
cis-ZEATIN (cZ) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 219.25;
crystalline; purity > 99% (HPLC) |
CAS: 32771-64-5; C10H13N5O |
|
001
0321 |
5 |
mg |
001
0322 |
10 |
mg |
001
0323 |
50 |
mg |
cis-ZEATIN RIBOSIDE (cZR) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-b-D-ribofuranosylpurine]
MW 351.37; crystalline; purity > 99% (HPLC) |
CAS: 15896-46-5; C15H21N5O5 |
|
001
0331 |
5 |
mg |
001
0332 |
10 |
mg |
001
0333 |
50 |
mg |
cis-ZEATIN-9-GLUCOSIDE (cZ9G) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-glucopyranosylpurine]
MW
381.39;
crystalline; purity > 95% (HPLC) |
CAS: 169565-72-4; C16H23N5O6 |
|
001
2891 |
1 |
mg |
001
2892 |
2 |
mg |
001
2893 |
5 |
mg |
cis-ZEATIN-7-GLUCOSIDE (cZ7G) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-7-b-D-glucopyranosylpurine]
MW 381.39; crystalline; purity > 95% (HPLC) |
CAS: 823188-69-8; C16H23N5O6 |
|
001
7851 |
100 | µg |
001
7852 |
200 | µg |
001
7853 |
500 | µg |
cis-ZEATIN-O-GLUCOSIDE (cZOG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)purine]
MW
381.39;
crystalline; purity > 95% (HPLC) |
CAS: 71866-93-8; C16H23N5O6 |
|
001
3391 |
1 |
mg |
001
3392 |
2 |
mg |
001
3393 |
5 |
mg |
cis-ZEATIN-O-GLUCOSIDE RIBOSIDE (cZROG) [6-((Z)-4-β-D-glucopyranosyloxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW
513.51;
crystalline; purity > 95% (HPLC) |
CAS: 125225-72-1; C21H31N5O10 |
|
001
3251 |
1 |
mg |
001
3252 |
2 |
mg |
001
3253 |
5 |
mg |
cis-ZEATIN RIBOSIDE-5'-MONOPHOSPHATE SODIUM SALT (cZMP) [6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine-5'-monophosphate disodium monohydrate]
MW 499.33;
crystalline; purity > 95% (HPLC) |
CAS: 125225-71-0; C15H20N5Na2O8P.H2O |
|
001
0591 |
1 |
mg |
001
0592 |
2 |
mg |
001
0593 |
5 |
mg |
2-METHYLTHIO-cis-ZEATIN (2MeScZ) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)purine]
MW 265.34;
crystalline; purity > 95% (HPLC) |
CAS: 52020-11-8; C11H15N5OS |
|
001
0541 |
1 |
mg |
001
0542 |
2 |
mg |
001
0543 |
5 |
mg |
2-METHYLTHIO-cis-ZEATIN RIBOSIDE (2MeScZR) [2-methylthio-6-((Z)-4-hydroxy-3-methylbut-2-enylamino)-9-β-D-ribofuranosylpurine]
MW
397.46;
crystalline; purity > 95% (HPLC) |
CAS: 52049-48-6; C16H23N5O5S |
|
001
0561 |
1 |
mg |
001
0562 |
2 |
mg |
001
0563 |
5 |
mg |